Clinical Study on the Safety and Efficacy of an Intravenous Infusion of NGGT003 in the Treatment of Hemophilia A
Overview
- Phase
- Early Phase 1
- Intervention
- NGGT003
- Conditions
- Hemophilia A
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Adverse events (AEs) and serious adverse events (SAEs)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT003 in hemophilia A patients. NGGT003 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human FVIII gene B domain deletion mutant (hFVIII BDD), and expresses human FVIII protein in the liver through intravenous injection.
Detailed Description
Hemophilia A (HA) is an X-linked recessive genetic disease caused by mutations in the FVIII gene on the X chromosome, leading to abnormal coagulation function. In the male population, the incidence rate of hemophilia A was about 1/5000, and female patients with hemophilia A were extremely rare. Type A hemophilia patients mainly exhibit a tendency for bleeding, with a wide range of bleeding sites and frequent recurrence, which can form hematoma and joint deformation. This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of a single intravenous infusion of NGGT003 in hemophilia A patients. 4-6 subjects will be enrolled and divided into 3 groups according to the principle of dose escalation, respectively administered intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg). All subjects will undergo 52 weeks of treatment observation and further 260 weeks of long-term follow-up.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Voluntarily sign the informed consent form;
- •Male, age ≥18 years old;
- •Diagnosed with hemophilia A according to the "Guidelines for Diagnosis and Treatment of Hemophilia A (2022 Edition)", and the endogenous FVIII activity level was \<1 IU/dL (\<1%);
- •The exposure days (EDs) of treatment with any recombinant or plasma-derived FVIII product were ≥150 days;
- •Anti-AAV neutralizing antibody titer ≤1:5, binding antibody titer ≤1:100;
- •Bleeding events and/or FVIII product injections have occurred within 12 weeks before screening;
- •No history of allergy to FVIII products;
- •FVIII inhibitor titer﹤0.6BU/mL;
- •Commitment to use other drugs during the study requires the consent of the investigator;
- •Willing and able to comply with study procedures and requirements;
Exclusion Criteria
- •Positive for hepatitis B surface antigen, hepatitis C, human immunodeficiency virus (HIV)，syphilis test;
- •Clinically significant abnormalities in liver function test: alanine aminotransferase (ALT) \>1.5 × upper limit of normal (ULN) and/or aspartate aminotransferase (AST) \>1.5× ULN;TBil）\>1.5×ULN；Serum creatinine (Scr) \>1.5×ULN; hemoglobin \<110g/L, platelets \<10e9/L;
- •History of being positive for FVIII inhibitors;
- •Have other bleeding factors except hemophilia;
- •Plan major surgery within 52 weeks;
- •Have contraindications to glucocorticoid, including but not limited to allergy to glucocorticoids, epilepsy, new unhealed fractures, in trauma repair period, uncontrolled infection, severe osteoporosis, etc, which assessed and determined by the investigators;
- •History of allergy to human albumin;
- •Have serious diseases or active infections in cardiovascular, respiratory, digestive tract, endocrine, renal, blood, nervous, mental and other systems before screening;
- •With hepatitis, cirrhosis, liver cancer or other major liver diseases;
- •History of malignant tumors;
Arms & Interventions
Experimental
3 doses of NGGT003 will be administered according to the principle of dose escalation
Intervention: NGGT003
Outcomes
Primary Outcomes
Adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 52 weeks
Incidence of AE and SAE, as assessed by physical examinations, clinical laboratory parameters and adverse event reporting
Changes in annualized bleeding rate (ABR)
Time Frame: 52 weeks
Changes in annualized bleeding rate (ABR) from baseline to 52 weeks.
Secondary Outcomes
- FVIII activity levels(52 weeks)
- HA-QOL scores(52 weeks)
- FVIII protein product infusions(52 weeks)
- Target joints(52 weeks)